Login to Your Account

Teva flunks orphan drug test with CRL on Auspex-developed chorea treatment

By Marie Powers
News Editor

Tuesday, May 31, 2016

Another billion-dollar-plus deal failed to play out as planned as the FDA dealt Teva Pharmaceutical Industries Ltd. a CRL on its NDA for SD-809 to treat chorea – involuntary writhing movements – associated with Huntington disease.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription